Authors
Latest:
Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCLAmitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.
Latest:
Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIsZosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.
Latest:
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLCClosing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Latest:
The Podcast by Fellows for FellowsDaniel J. Hausrath, MD, discusses a collaborative effort to produce a podcast for fellows that reviews the fundamentals, core concepts, and important management approaches in the field, as determined by the latest evidence and expert opinion.
Latest:
Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast CancerCristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.
Latest:
Dr. Greene on the Future of Personalized Therapy in Prostate CancerKirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.
Latest:
Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALLNovel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
Holistic and Multidisciplinary Approaches to Multiple Myeloma ManagementClosing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.
Latest:
Dr Alfonso Piérola on Unmet Needs in Higher-Risk MDSAna Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.
Latest:
MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast CancerPraveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Latest:
Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, LymphomasMatthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.
Latest:
Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLCEstelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.
Latest:
Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple MyelomaMeral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.
Latest:
Dr Yaeger on the Implications of Data With Second-Line Sotorasib Plus Panitumumab in mCRCRona Yaeger, MD, discusses the implications of data with second-line sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.
Latest:
Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast CancerNicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.
Latest:
Future Directions for mCRC ManagementGerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Latest:
Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.
Latest:
Dr. Santa-Maria on Trastuzumab Deruxtecan in HER2-low TNBCCesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.
Latest:
Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast CancerNadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.
Latest:
Dr Giles on the Importance of Shared Decision Making When Managing GU CancersRachel Giles, MD, PhD, discusses the importance of incorporating shared decision making in the treatment of patients with genitourinary cancers.
Latest:
Dr. Jasmine Zain: Challenges in T-Cell Lymphoma TreatmentJasmine Zain, MD, director of the T-cell Lymphoma Program, professor of hematology and hematopoietic stem cell transplantation, of City of Hope National Medical Center, discusses the challenges of treatment for patients with T-cell lymphoma.
Latest:
Dr DeBernardo on an Ovarian Cancer Patient Case StudyRobert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.
Latest:
Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRCAlaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.
Latest:
Dr. Khushman on Best Practices in the Management of GI CancersMoh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.
Latest:
Palliative Care Can Address Gaps in Oncology LandscapePalliative medicine has evolved to become a standard for high-quality cancer care, helping patients relieve suffering throughout their journey, improving quality of life, and prolonging survivorship.
Latest:
FDA Panel Gives Beti-Cel Unanimous Support of Benefit in β-thalassemiaThe FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted unanimously in favor of the benefit of betibeglogene autotemcel for the treatment of transfusion-dependent β-thalassemia in adult and pediatric patients with a non–β0/β0 genotype.
Latest:
Kevin Hakimi on the Rationale of the PADRES Trial in RCCKevin Hakimi, discusses the rationale for the phase 2 PADRES trial in clear cell renal cell carcinoma.
Latest:
Multidisciplinary Care for Patients with CRCClinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.
